ACADIA Pharmaceuticals Inc. (ACAD)
| Market Cap | 4.55B +20.0% |
| Revenue (ttm) | 1.10B +9.9% |
| Net Income | 375.65M +64.1% |
| EPS | 2.20 +60.4% |
| Shares Out | 171.24M |
| PE Ratio | 12.09 |
| Forward PE | 66.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,298,574 |
| Open | 26.13 |
| Previous Close | 26.34 |
| Day's Range | 25.87 - 26.58 |
| 52-Week Range | 19.69 - 28.35 |
| Beta | 0.80 |
| Analysts | Buy |
| Price Target | 32.95 (+24.11%) |
| Earnings Date | Aug 4, 2026 |
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy... [Read more]
Financial Performance
In 2025, ACADIA Pharmaceuticals's revenue was $1.07 billion, an increase of 11.87% compared to the previous year's $957.80 million. Earnings were $391.00 million, an increase of 72.66%.
Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price target is $32.95, which is an increase of 24.11% from the latest price.
News
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, Augu...
Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital
BMO Capital transferred its coverage on Acadia Pharmaceuticals (ACAD) to who raised the firm’s price target to $36 from $34 and keeps an Outperform rating on the shares. The analyst…
Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $24 and keeps a Hold rating on the shares. While the firm thinks Acadia…
Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
Stifel analyst Paul Matteis raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $25 from $24 and keeps a Hold rating on the shares. Stifel believes Acadia has given…
Acadia Pharmaceuticals receives FDA Fast Track designation for remlifanserin
Acadia Pharmaceuticals (ACAD) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to remlifanserin, an investigational, highly selective, 5-HT2A receptor inve...
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to remlifanserin, an investig...
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S....
Acadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $29 and keeps an Outperform rating on the shares as part of a…
Acadia Pharmaceuticals appoints Carl Segerstorm as CPO
Acadia Pharmaceuticals (ACAD) announced the appointment of Carl Segerstrom as Chief People Officer. Carl will lead the company’s global people and culture strategy, supporting its next phase of growth...
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global...
Acadia Pharmaceuticals price target raised to $30 from $29 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $30 from $29 and keeps a Buy rating on the shares after the company announced a…
Acadia Pharmaceuticals price target raised to $37 from $32 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $32 and keeps a Buy rating on the shares. The firm says Daybue…
Acadia Pharmaceuticals price target raised to $36 from $32 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $32 and keeps a Buy rating on the shares. The company announced that the…
Citi adds ‘upside 90-day catalyst watch’ on Acadia Pharmaceuticals
Citi added an “upside 90-day catalyst watch” on Acadia Pharmaceuticals (ACAD) while keeping a Buy rating on the shares with a $35 price target Citi says the stock could rally…
Acadia Pharmaceuticals price target raised to $35 from $32 at Citi
Citi raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $35 from $32 and keeps a Buy rating on the shares after the Committee for Medicinal Products for Human…
Acadia Pharmaceuticals rises 13.4%
Acadia Pharmaceuticals (ACAD) is up 13.4%, or $3.17 to $26.89.
Acadia Pharmaceuticals Stock (ACAD) Jumps on a Positive CHMP Review
Acadia Pharmaceuticals stock was up on Friday alongside a positive review of its Rett syndrome treatment.
Acadia Pharmaceuticals rises 9.9%
Acadia Pharmaceuticals (ACAD) is up 9.9%, or $2.35 to $26.07.
Acadia Pharmaceuticals: Daybu recommended for approval in EU by CHMP
Acadia Pharmaceuticals (ACAD) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion following a re-examination procedure, re...
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted...
ACADIA Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
Remlifanserin shows promise for ADP with improved safety and efficacy strategies, while NUPLAZID's expanded sales force is driving new prescriber growth. DAYBUE's new STIX formulation is well received, supporting higher persistence, and regulatory and pipeline progress continues.
ACADIA Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Management outlined commercial and pipeline progress, including ambitious sales targets for key brands, innovative product launches, and a robust late-stage pipeline. Clinical updates highlighted upcoming data for Alzheimer's and depression programs, with a focus on unmet needs and regulatory strategy.
Acadia Pharmaceuticals price target lowered to $32 from $33 at Citi
Citi lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $32 from $33 and keeps a Buy rating on the shares.
Acadia Pharmaceuticals reports Q1 EPS 2c, consensus 8c
Reports Q1 revenue $268M, consensus $280.27M. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales…
Acadia Pharmaceuticals backs FY26 revenue view $1.22B-$1.28B, consensus $1.25B
16:12 EDT Acadia Pharmaceuticals (ACAD) backs FY26 revenue view $1.22B-$1.28B, consensus $1.25B